Clinical observations of nedaplatin combined with paclitaxel treating advanced esophageal carcinoma
Wang Li
Abstract：Objective To evaluate the efficiency and safety of nedaplatin combined with paclitaxel treating advanced esophageal carcinoma. Methods Sixty-eight initial-treated patients with advanced esophageal squamous carcinoma were randomly divided into two groups: observation group (thirty-four patients with advanced esophageal carcinoma) received chemotherapy with nedaplatin and paclitaxel; control group (thirty-four patients with advanced esophageal carcinoma) received no more than six courses of chemotherapy with cisplatin and paclitaxel, and each course was three weeks. Results The effective rate of observation group and control group was respectively 52.9% (18/34) and 47.1% (16/34). The difference between the two groups was not statistically significant (P>0.05). Most of patients in the groups had mild-to-moderate adverse reactions; the adverse reactions of control group were nausea and vomiting. Compared with control group, leukopenia of observation group was grade I and thrombocytopenia was grade II. The differences of grade 0, grade II and III of nausea and vomiting had statistical significant (P<0.05). Conclusion Nedaplatin combined with paclitaxel treating advanced esophageal carcinoma has a similar effectiveness with less adverse effects than cisplatin combined with paclitaxel.
Keywords：Advanced esophageal carcinomaNedaplatinPaclitaxel
Publication Date：2014-03-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 349-351 )